<DOC>
	<DOC>NCT01069705</DOC>
	<brief_summary>This is an open-label, single arm (uncontrolled) study in patients suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 and extension study one CTBM100C2303E1 (all visits), who were proven infected with Pseudomonas aeruginosa at enrollment into CTBM100C2303.</brief_summary>
	<brief_title>Second Open Label Extension to Bridging Study CTBM100C2303</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Completed all visits in study CTBM100C2303 and CTBM100C2303E1, and visit 11 of study CTBM100C2303E1 took place not more than 5 days before enrollment into this study Confirmed diagnosis of cystic fibrosis patients with P. aeruginosa infection. FEV1 at screening (at start of study CTBM100C2303) must be between 25% and 80% of normal predicted values. Any use of inhaled antipseudomonal antibiotics between the termination of the trial CTMB100C2303E1 and the enrollment into this study. Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tobramycin Inhalation Powder</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Lung diseases</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
	<keyword>Treatment of pulmonary infections with P. aeruginosa in cystic fibrosis patients</keyword>
</DOC>